Intra-Cellular Therapies (ITCI) shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1% loss over the past four weeks.The sudden soaring of the stock price was observed after ITCI announced that it has entered into a settlement agreement with Sandoz regarding the Caplyta (lumateperone) patent litigation. The settlement agreement resolves the patent litigation brought ...